中危宫颈癌患者辅助放化疗与单纯放疗的比较
这项基于美国国家癌症数据库的队列研究纳入2010年至2020年接受根治性子宫切除术后辅助放疗的1116例中危FIGO IB期宫颈癌患者,其中486例(43.5%)接受同步放化疗。倾向评分匹配后868例分析显示,放化疗组与单纯放疗组5年生存率均为87%(HR 0.85,95%CI 0.59-1.23,P=0.38),作者认为加用化疗未改善总生存。
要点
- 中危宫颈癌辅助放化疗与单纯放疗5年生存率均为87%,无显著差异。
- 腺癌或腺鳞癌较鳞癌更常接受化疗(RR 1.26,95%CI 1.10-1.44)。
- 肿瘤大于4cm较2-4cm更常接受化疗(RR 1.31,95%CI 1.14-1.51)。
核心结论
- 该队列研究结果提示,中危宫颈癌患者辅助放疗中加用化疗与总生存改善无关。
研究设计与样本
- 在美国委员会癌症认证中心开展的队列研究,使用国家癌症数据库前瞻性收集的数据。
- 纳入2010年1月至2020年12月诊断为2018 FIGO IB期宫颈癌(鳞癌、腺鳞癌或腺癌)且根治性子宫切除术后接受辅助放疗的中危患者。
- 缺失变量采用多重插补,并进行1:1倾向评分匹配以平衡基线特征。
- 采用Kaplan-Meier分析和比例风险模型比较组间死亡风险。
主要发现
- 共纳入1116例患者(平均[SD]年龄47[12]岁),其中486例(43.5%)接受同步放化疗。
- 腺癌或腺鳞癌较鳞癌更常接受化疗(RR 1.26,95%CI 1.10-1.44)。
- 肿瘤大于4cm较2-4cm更常接受化疗(RR 1.31,95%CI 1.14-1.51)。
- 倾向评分匹配后868例患者 covariates 平衡,放化疗组与单纯放疗组5年生存率均为87%(HR 0.85,95%CI 0.59-1.23,P=0.38)。
- 按肿瘤大小、组织学、淋巴血管间隙浸润、手术方式或辅助近距离放疗定义的亚组中,化疗与生存均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Optimal adjuvant treatment for patients with intermediate-risk cervical cancer remains controversial, and the benefit of adding chemotherapy to radiotherapy in this population is uncertain. OBJECTIVE: To evaluate whether adjuvant chemoradiotherapy is associated with improved overall survival compared with radiotherapy alone in patients with intermediate-risk cervical cancer. Secondary objectives included identifying clinical factors associated with the use of chemoradiotherapy. DESIGN, SETTING, AND PARTICIPANTS: A cohort study was conducted at Commission on Cancer-accredited centers across the US using prospectively collected data from the National Cancer Database that focused on patients with a diagnosis of 2018 International Federation of Gynecology and Obstetrics stage IB cervical carcinoma (squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma) of intermediate risk who were undergoing adjuvant radiotherapy treatment after radical hysterectomy from January 2010 through December 2020. Missing variables were multiple imputed, and propensity score matching (1:1) was performed to balance baseline characteristics. A Kaplan-Meier analysis and proportional hazard models were used to compare the hazard of death between the groups. EXPOSURE: Adjuvant radiotherapy alone vs concurrent chemoradiotherapy. MAIN OUTCOME AND MEASURE: The primary outcome was time to death or last follow-up. RESULTS: A total of 1116 patients (mean [SD] age, 47 [12] years) were identified, of whom 486 (43.5%) received concurrent chemoradiotherapy. Chemotherapy was administered more frequently among those with adenocarcinoma or adenosquamous histology compared with squamous cell carcinoma (risk ratio [RR], 1.26; 95% CI, 1.10-1.44) and those with tumors larger than 4 cm (compared with tumors measuring 2-4 cm; RR, 1.31; 95% CI, 1.14-1.51). Propensity score matching yielded a cohort of 868 patients with balanced covariates. Patients who received chemoradiotherapy had similar overall survival (5- year survival, 87%) as those who received radiotherapy alone (5-year survival, 87%; hazard ratio, 0.85; 95% CI, 0.59-1.23; P = .38). There were no significant differences in survival associated with chemotherapy receipt among subgroups defined by tumor size, histology, presence of lymphovascular space invasion, surgical approach, or receipt of adjuvant brachytherapy. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that adding chemotherapy to radiotherapy was not associated with improved overall survival for patients with intermediate-risk cervical cancer.
引用
- Agustí N, Viveros-Carreño D, Wu CF, et al. Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer. JAMA Oncol. 2025. PMID: 40079948. doi:10.1001/jamaoncol.2025.0146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。